Background: Obesity is associated with higher risk of aggressive prostate cancer and alters circulating
Introduction
Obesity is associated with lower risk of localized prostate cancer and higher risk of aggressive and fatal cancer (1) . Adiponectin (2) and insulin (3) are hormones whose circulating levels are influenced by obesity and may play a role in carcinogenesis. The association of adiponectin with prostate cancer was investigated by two prospective studies (4, 5) which yielded conflicting results.
Whereas Li et al. (4) reported a significant inverse association of adiponectin with both high grade and lethal prostate cancer, Touvier et al. (5) found no significant association with prostate cancer overall. As summarized in a recent review of diabetes and prostate cancer (6) , several studies have found inconsistent results for the association of insulin or c-peptide, a marker of insulin secretion, with prostate cancer risk. We examined associations of plasma adiponectin and c-peptide levels with aggressive prostate cancer in a nested case-control study within the Cancer Prevention Study II (CPS-II) Nutrition Cohort. With 272 cases, this is the largest study of these circulating markers and risk of aggressive prostate cancer.
Materials and Methods
Study Population. Men in this analysis were from the 86,404 male participants in the CPS-II Nutrition Cohort, a prospective study of cancer incidence begun in 1992. Details of the recruitment and characteristics of this cohort have been described previously (7) . Incident cancers were self-reported on follow-up questionnaires sent to participants in 1997 and every two years thereafter and were verified through medical records or state cancer registries. Additional cancers were ascertained through linkage to the National Death Index. Blood samples were collected on a subset of cohort participants (17, 411 men) between 1998 and 2001 and were stored in liquid nitrogen vapor phase. (4+3) and/or stage T3 or T4 at diagnosis, or ultimately fatal prostate cancer of unknown stage and grade at diagnosis (N=2). For each case, one control, matched on date of birth (±6 mo), date of blood collection (±6 mo), and race/ethnicity, was randomly selected from men with no history of cancer on the diagnosis date of the case.
Laboratory Procedures. Plasma adiponectin and c-peptide levels were measured in the laboratory of Dr. Michael Pollak (McGill University, Montreal, Canada) using commercially available ELISA assays.
Samples were analyzed in batches of 37, which included 3 quality control replicates. Coefficients of variation (CV) and intraclass correlation coefficients (ICC) based on these replicates were 6.5% and 97.3% for adiponectin and 7.2% and 98.3% for c-peptide.
Statistical Analyses. Quartiles of adiponectin and c-peptide levels were defined based on their distribution among controls. The association of each analyte with prostate cancer risk was determined using conditional logistic regression to generate odds ratios (OR) and 95% confidence intervals (CI). All models were adjusted for BMI, family history of prostate cancer, physical activity, total calcium intake, and energy intake. Adjustment for education, alcohol intake, smoking, history of diabetes, and aspirin use did not alter the risk estimates and therefore these factors were not included in multivariateadjusted models. Adjustment of adiponectin levels for c-peptide levels and vice versa also did not alter risk estimates.
Results
The aggressive prostate cancer cases and controls in this study were similar with respect to age and race because of matching (Table 1) . Aggressive prostate cancer cases were less likely to report a history of ever having had a prostate-specific antigen (PSA) test on the 1997 follow-up survey (before blood draw), although most of the cases and controls reported some history of PSA testing. Cases were more likely than controls to report a family history of prostate cancer.
Adiponectin and c-peptide were not associated with all aggressive prostate cancer in multivariate-adjusted models (Table 2 ). For adiponectin, results were similar when the cases were further restricted to high-risk prostate cancer (Gleason score ≥8 and and/or tumor extent T3-T4) as defined by National Comprehensive Cancer Network (NCCN) guidelines (8) (Table 2). For c-peptide, the highest quartile, compared to the lowest, was associated with an elevated, albeit not significant, risk of high risk prostate cancer (OR=1.34, 95% CI: 0.9-2.62). Excluding subjects diagnosed within 2 years of blood draw did not substantially change the associations (data not shown).
Discussion
This study included 272 aggressive prostate cancer cases, more than any previous study cpeptide or adiponectin levels (1, 2) . Despite the comparatively large sample size, we found no evidence that differences in pre-diagnostic levels of adiponectin were associated with risk of aggressive prostate cancer. However, we cannot preclude the possibility that high levels of c-pepide may be associated with the highest-risk aggressive prostate cancer. 
